Market Newsdesk

Atlanta, GA, April 07, 2021 (GLOBE NEWSWIRE) — Supersapiens is proud to become the 2021 and 2022 title sponsor for the IRONMAN World Championship, held annually in Kona, Hawaii. The deal also includes four of Europe’s most renowned races, IRONMAN UK, IRONMAN Hamburg, IRONMAN France, and IRONMAN Emilia Romagna.

The Supersapiens training ecosystem, powered by Abbott’s Libre Sense Glucose Sport Biosensor and the Supersapiens app, empowers athletes to optimize fueling, maximize training, and increase performance gains. Their set of data interpretation tools is leading the future of fueling and sports performance.

Today’s announcement expands on their existing partnership, announced earlier this year when Supersapiens became the Official Real-Time Energy Management System Partner for 26 IRONMAN® and IRONMAN 70.3® events (full list below). 

“As athletes, we understand the challenge, struggle, and commitment of training for endurance events like IRONMAN and IRONMAN 70.3,” says Supersapiens Founder and CEO Phil Southerland. “We are truly excited to work with IRONMAN athletes to take the gambling out of race day. These superhumans put so much time and energy into training for one or two target events each year. There is too much on the line for them to take a chance on fueling during those races. We look forward to seeing the personal satisfaction of goals achieved by IRONMAN athletes around the world.” 

A partnership with global healthcare leader Abbott makes Supersapiens the only energy management ecosystem that directly integrates with a Bluetooth-enabled CGM (continuous glucose monitor) — the Abbott Libre Sense Glucose Sport Biosensor. This strategic partnership means that Supersapiens can offer athletes access to truly meaningful and actionable glucose data — real-time glucose levels transmitted directly to their phone.

“The IRONMAN World Championship is the pinnacle of Triathlon,” says Supersapiens Vice President of Marketing and IRONMAN athlete, Travis McKenzie. “At our core, Supersapiens is a company of dedicated athletes who inherently understand the road to Kona. Until now, effectively fueling an athlete’s training, recovery, and racing has been a guessing game. Using this innovative technology, athletes can get a step closer towards mastering the fourth discipline of Triathlon.”

Additionally, IRONMAN and Supersapiens will introduce the Supersapiens Sub Club Training Platform giving athletes access to education, coaching and support to reach specific time goals in their upcoming IRONMAN events. The program will roll out in late-April. Supported by the vast IRONMAN U Coaching Network, athletes will have access to exclusive content and expert knowledge to master fueling for their training, recovery, and racing needs.

The IRONMAN Group CEO, Andrew Messick said, “As many athletes learn the hard way, a stellar bike split becomes irrelevant if sub-par fuelling strategies cause a bonk later on in the race. The IRONMAN World Championship represents the pinnacle in our sport, and Supersapiens’ innovative energy management ecosystem and real-time glucose levels insight will prove invaluable in an athlete’s endeavour for the ultimate red-carpet glory. We are excited to extend our partnership with Supersapiens and give athletes every advantage to achieve their optimal performance goals.”

The Supersapiens ecosystem powered by Abbott’s Libre Sense is now available in Austria, France, Germany, Ireland, Italy, Luxembourg, Switzerland, and the United Kingdom. For markets where Supersapiens has yet to be released, athletes can secure their spot on the waitlist. Learn more about the full line of Supersapiens products and become a member at www.supersapiens.com.

2021 IRONMAN Events:

• IRONMAN 70.3 Kraichgau
• IRONMAN 70.3 Switzerland
• IRONMAN 70.3 Luxembourg
• IRONMAN Frankfurt (European Championship)
• Supersapiens | IRONMAN UK
• IRONMAN Austria
• IRONMAN 70.3 Les Sables d’Olonne
• IRONMAN Switzerland Thun
• IRONMAN 70.3 Ireland
• IRONMAN 70.3 Graz
• IRONMAN Ireland-Cork
• IRONMAN 70.3 Vichy
• IRONMAN Vichy
• Supersapiens | IRONMAN Hamburg
• IRONMAN 70.3 Duisburg
• IRONMAN 70.3 Zell am See
• Supersapiens | IRONMAN France
• IRONMAN 70.3 Nice
• IRONMAN Wales
• IRONMAN 70.3 Weymouth
• IRONMAN 70.3 Pays d’Aix
• IRONMAN 70.3 Emilia Romagna
• Supersapiens | IRONMAN Italy Emilie Romangna
• IRONMAN 70.3 Venice
• Supersapiens | IRONMAN World Championship Kona
• IRONMAN 70.3 Sardegna

About Supersapiens

Supersapiens is a US-based sports technology company focused on energy management systems to empower athletes to effectively manage in-training fueling to sustain high-intensity work, properly manage glucose levels to maximize recovery, and achieve bigger performance gains.

The Abbott Libre Sense Glucose Sport Biosensor is intended for athletes to measure glucose. Athletes are defined as individuals who perform exercise with the purpose of improving wellness and performance. When used with a compatible product, the biosensor allows athletes to correlate their glucose levels and their athletic performance. The biosensor is not intended for use in the diagnosis, treatment, or monitoring of a disease.

The Supersapiens ecosystem, including the Abbott Libre Sense Glucose Sport Biosensor, is not yet available for sale in the U.S. For a full list of references and FAQs, please visit our

Education Hub

and

Help Center

.

About The IRONMAN Group

The IRONMAN Group operates a global portfolio of events that includes the IRONMAN Triathlon Series, the IRONMAN 70.3 Triathlon Series, the IRONMAN Virtual Racing (VR) Series, 5150 Triathlon Series, the Rock ‘n’ Roll Marathon Series, the Rock ‘n’ Roll Virtual Running Series, IRONKIDS, ITU World Triathlon Series, premier running events including the Standard Chartered Singapore Marathon and The Sun-Herald City2Surf, Ultra-Trail World Tour events including Tarawera Ultra and Ultra-Trail Australia, mountain bike races including the Absa Cape Epic, road cycling events, and other multisport races. The IRONMAN Group is the largest operator of mass participation sports in the world and provides more than a million participants annually the benefits of endurance sports through the company’s vast offerings. Since the inception of the iconic IRONMAN brand and its first event in 1978, athletes have proven that ANYTHING IS POSSIBLE by crossing finish lines around the world. Beginning as a single race, The IRONMAN Group has grown to become a global sensation with hundreds of events across 55+ countries. The IRONMAN Group is owned by Advance (www.advance.com), a private, family-owned business. For more information, visit www.ironman.com.

Attachment

• Ironman Partnership – 01

Data from Initial Patient Cohorts of Phase 2 AFFINITY Study Expected to be Reported in 2022

SEATTLE, April 07, 2021 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient has been dosed in the AFFINITY Study, a phase 2 clinical trial evaluating the efficacy and safety of atrasentan, a potent and selective inhibitor of the endothelin A receptor, in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

“Initiation of the phase 2 AFFINITY Study is an important step in evaluating atrasentan across multiple proteinuric glomerular diseases for which there are currently limited treatment options,” said Alan Glicklich, M.D., chief medical officer of Chinook. “Atrasentan’s proteinuria-lowering, anti-fibrotic and anti-inflammatory properties have the potential to provide therapeutic benefit in a variety of chronic kidney diseases. Data generated in the AFFINITY Study will help inform the development strategy for atrasentan in these additional indications in parallel to our phase 3 ALIGN Study in IgA nephropathy.”

About the AFFINITY Study

The AFFINITY Study (see www.clinicaltrials.gov, identifier NCT04573920) is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function. Four initial cohorts will consist of patients with: IgA nephropathy (IgAN) with urine protein to creatinine ratio (UPCR) of 0.5 to less than 1.0 g/g, focal segmental glomerulosclerosis (FSGS), Alport syndrome and diabetic kidney disease (DKD) in combination with an SGLT2 inhibitor. Additional cohorts may be added to the study over time. Approximately 20 patients will be enrolled in each cohort to receive 0.75 mg atrasentan for 52 weeks. Patients in all cohorts will continue receiving a maximally tolerated and stable dose of a RAS inhibitor as standard of care. The AFFINITY Study will enroll patients in the United States, Australia, South Korea, the United Kingdom, Italy and Spain.

The primary efficacy endpoint of the AFFINITY Study is the effect on proteinuria as measured by urine protein to creatinine ratio (UPCR) in patients with IgAN, FSGS and Alport syndrome and the change in albuminuria as measured by urine albumin to creatinine (UACR) in patients with DKD, from baseline to 12 weeks. Chinook expects to report data from initial cohorts of patients in the AFFINITY Study during 2022.

About Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1b trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.

Cautionary Note on Forward-Looking Statements

Certain of the statements made in this press release are forward looking, including those relating to Chinook’s business, future operations, advancement of its product candidates and product pipeline, clinical development of its product candidates, including expectations regarding timing of initiation and results of clinical trials. In some cases, you can identify these statements by forward-looking words such as “may,” “will,” “continue,” “anticipate,” “intend,” “could,” “project,” “expect” or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, including initiation of clinical trials, whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that may be more advanced or have greater resources than we do, our ability to obtain and adequately protect intellectual property rights for our product candidates and the effects of COVID-19 on our clinical programs and business operations. Many of these risks are described in greater detail in our filings with the SEC. Any forward-looking statements in this press release speak only as of the date of this press release. Chinook assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:

Noopur Liffick
Vice President, Investor Relations & Corporate Communications
[email protected]
[email protected]

Littleton, Colorado, April 07, 2021 (GLOBE NEWSWIRE) — AEI Corporation, a multi-disciplinary forensic engineering firm providing a full range of investigative analysis, testing, and expert witness services, is pleased to announce changes to its leadership team. 

As part of AEI’s ownership succession plan, former AEI President and Founder Jay Freeman will remain with AEI as a Senior Project Engineer, while John Schumacher will assume the responsibilities and leadership role of President. John, along with longtime AEI colleagues Dennis Shelp and Zach Jason will comprise the executive leadership team moving forward. As established industry leaders, John, Dennis, and Zach bring decades of experience with a proven track record in the field of forensic engineering. 

“John, Dennis, and Zach have been a core part of the company since it was founded in 2005 and remain dedicated to providing high-quality engineering, consulting, and litigation support for our clients,” said AEI Founder Jay Freeman. “Clients can expect the same level of service provided by the colleagues they know and trust.”    

“On the surface, our role is to uncover the facts and tell the story of what happened when something goes wrong,” said AEI President John Schumacher. “What really drives us is the opportunity to help our clients determine what steps to take next.”

With more than 175 years of combined experience in forensic engineering and investigations, the licensed engineers and consultants at AEI Corporation are known throughout the industry for their expertise in forensic engineering and investigations. AEI is also equipped to handle a full range of testing and analysis and provide expert testimony. 

ABOUT AEI Corporation

Since 2005, AEI’s experts have utilized forensic engineering and their expertise to help determine the causes of incidents for a broad spectrum of clients.

AEI’s leadership team is comprised of John L. Schumacher, Dennis E. Shelp, and Zachary J. Jason. Founder John M. (Jay) Freeman continues to work as a full-time Senior Project Engineer.

AEI’s strengths include the versatility of its experts and the diversity of investigations where they can be of assistance. AEI is based in Littleton, CO, and performs investigations throughout the United States, Canada, and Mexico, with projects occasionally in Asia and Africa.

AEI’s 14,000+ square foot facility in Littleton, CO gives them the ability to facilitate and conduct large laboratory inspections. AEI has the right equipment to complete both demonstrative and non-destructive testing, including a Keyence microscope, FTIR, hood system, X-Ray, and much more.

AEI’s clients include, but are not limited to, propane and natural gas companies, gas appliance manufacturers, electrical utilities, electrical equipment manufacturers, law firms, insurance carriers, and representatives in the transportation industry. We know that successful forensic investigations begin with asking the right questions, and then following through until hidden causes are discovered and problems are solved.

Attachment

• Partners picture (2)